NASDAQ · HCM

HUTCHMED (China) Limited American

$11.12 +$0.11 (+1.00%) 1D After hours
Charting by TradingView

Key Metrics

$1.89B
Market cap
4.14×
P/E · TTM
$548.51M
Revenue · TTM
$456.91M
Net income
EPS · TTM $0.53
Dividend yield —
Free cash flow −$78.81M
Beta · 1Y 0.65
EBITDA · TTM −$25.85M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 22
    From its Apr 17 high, the share price fell 37%.

    Peak close $15.74 on Apr 17; trough close $9.99 on Jun 22. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -37%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.89B
Enterprise value$619.06M
Shares outstanding172.0M
52-wk range$9.77 – $19.50
Avg volume · 20D206.3K
Net cash $1.27B
Book value / share$1.42
ExchangeNASDAQ
About HUTCHMED (China) Limited American
IPO dateMar 17, 2016
Employees1796

HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E4.14
P/S3.45
P/FCF—
EV/EBITDA—
EV/Sales1.13
Graham №$4.10

Profitability

Gross —
Operating -7.1%
Net 83.3%
FCF -14.4%
ROE / ROIC 45.7% · 94.4%

Financial Health

Current ratio4.96
Quick ratio4.83
Debt / equity0.08
Debt / EBITDA -3.60
Net cash $1.27B
Working capital$1.25B

Cash Flow · TTM

Operating CF −$64.66M
Capex −$14.15M
Free cash flow −$78.81M
Buybacks $9.07M
Dividends paid —
Shareholder yield 0.5%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

3.1
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$4.10 vs $11.12
Trades 2.7× above classic defensive value — priced for growth
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings